Skip to main content
Top
Published in: Journal of Neural Transmission 4/2013

Open Access 01-04-2013 | Neurology and Preclinical Neurological Studies - Review Article

Sleep and non-motor symptoms in Parkinson’s disease

Authors: Antonia Maass, Heinz Reichmann

Published in: Journal of Neural Transmission | Issue 4/2013

Login to get access

Abstract

Beyond the cardinal motor symptoms, bradykinesia, rigidity, tremor and postural instability, defining the diagnosis of Parkinson’s disease, there is a big spectrum of non-motor features that patients may suffer from and that may reduce their quality of life. Non-motor symptoms are not only frequent but also often under-reported by patients and caregivers. As they are frequently under-recognized by clinicians, they remain consequently under-treated. This review wants to give a short overview of the importance of non-motor symptoms on patients’ quality of life and helpful assessment tools that might facilitate recognition of non-motor features during clinical setting. Given the wide range of non-motor symptoms in Parkinson’s disease, we concentrate on common issues such as depression and sleep disorders like sleep-onset insomnia or sleep maintenance insomnia and restless legs syndrome. Thereby, we present some recent studies that have investigated the efficacy of dopaminergic drugs, especially dopamine agonists, revealing possible treatment strategies and thus improving disease management.
Literature
go back to reference Aurora RN, Zak RS, Maganti RK, Auerbach SH, Casey KR, Chowdhuri S, Karippot A et al (2010) Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 6(1):85–95PubMed Aurora RN, Zak RS, Maganti RK, Auerbach SH, Casey KR, Chowdhuri S, Karippot A et al (2010) Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 6(1):85–95PubMed
go back to reference Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, Zappia M, Musch B, Depression/Parkinson Italian Study Group (2006) Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol 253(5):601–607PubMedCrossRef Barone P, Scarzella L, Marconi R, Antonini A, Morgante L, Bracco F, Zappia M, Musch B, Depression/Parkinson Italian Study Group (2006) Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol 253(5):601–607PubMedCrossRef
go back to reference Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24(11):1641–1649PubMedCrossRef Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24(11):1641–1649PubMedCrossRef
go back to reference Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D (2010) Pramipexole for the treatment of depressive symptoms in patients with parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9(6):573–580PubMedCrossRef Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D (2010) Pramipexole for the treatment of depressive symptoms in patients with parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9(6):573–580PubMedCrossRef
go back to reference Chaudhuri KR, Naidu Y (2008) Early Parkinson’s disease and non-motor issues. J Neurol 255(Suppl 5):33–38PubMedCrossRef Chaudhuri KR, Naidu Y (2008) Early Parkinson’s disease and non-motor issues. J Neurol 255(Suppl 5):33–38PubMedCrossRef
go back to reference Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8(5):464–474PubMedCrossRef Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8(5):464–474PubMedCrossRef
go back to reference Chaudhuri KR, Yates L, Martinez-Martin P (2005) The non-motor symptom complex of Parkinson’s disease: a comprehensive assessment is essential. Curr Neurol Neurosci Rep 5(4):275–283PubMedCrossRef Chaudhuri KR, Yates L, Martinez-Martin P (2005) The non-motor symptom complex of Parkinson’s disease: a comprehensive assessment is essential. Curr Neurol Neurosci Rep 5(4):275–283PubMedCrossRef
go back to reference Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, Brown RG et al (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord 21(7):916–923PubMedCrossRef Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, Brown RG et al (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord 21(7):916–923PubMedCrossRef
go back to reference Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-Payo B, Tluk S, Ruessmann A et al (2010) The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 25(6):704–709PubMedCrossRef Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-Payo B, Tluk S, Ruessmann A et al (2010) The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 25(6):704–709PubMedCrossRef
go back to reference Dhawan V, Healy DG, Pal S, Chaudhuri KR (2006) Sleep-related problems of Parkinson’s disease. Age Ageing 35(3):220–228PubMedCrossRef Dhawan V, Healy DG, Pal S, Chaudhuri KR (2006) Sleep-related problems of Parkinson’s disease. Age Ageing 35(3):220–228PubMedCrossRef
go back to reference Dunlop BW, Nemeroff CB (2007) The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 64(3):327–337PubMedCrossRef Dunlop BW, Nemeroff CB (2007) The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 64(3):327–337PubMedCrossRef
go back to reference Fantini ML, Gagnon JF, Filipini D, Montplaisir J (2003) The effects of pramipexole in REM sleep behavior disorder. Neurology 61(10):1418–1420PubMedCrossRef Fantini ML, Gagnon JF, Filipini D, Montplaisir J (2003) The effects of pramipexole in REM sleep behavior disorder. Neurology 61(10):1418–1420PubMedCrossRef
go back to reference Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S (1999) Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52(9):1908–1910PubMedCrossRef Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S (1999) Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52(9):1908–1910PubMedCrossRef
go back to reference Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, O’Keeffe S, Trenkwalder C, Hogl B, Benes H et al (2012) European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol 19(11):1385–1396PubMedCrossRef Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, O’Keeffe S, Trenkwalder C, Hogl B, Benes H et al (2012) European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol 19(11):1385–1396PubMedCrossRef
go back to reference Giladi N, Fichtner A, Poewe W, Boroojerdi B (2010) Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson’s disease. J Neural Transm 117(12):1395–1399PubMedCrossRef Giladi N, Fichtner A, Poewe W, Boroojerdi B (2010) Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson’s disease. J Neural Transm 117(12):1395–1399PubMedCrossRef
go back to reference Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP (2006) Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology 67(5):853–858PubMedCrossRef Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP (2006) Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology 67(5):853–858PubMedCrossRef
go back to reference Global Parkinson’s Disease Survey Steering Committee (2002) Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord 17(1):60–67CrossRef Global Parkinson’s Disease Survey Steering Committee (2002) Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord 17(1):60–67CrossRef
go back to reference Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H (2007) Olfactory loss may be a first sign of idiopathic Parkinson’s disease. Mov Disord 22(6):839–842PubMedCrossRef Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H (2007) Olfactory loss may be a first sign of idiopathic Parkinson’s disease. Mov Disord 22(6):839–842PubMedCrossRef
go back to reference Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K et al (2009) Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24(10):1468–1474PubMedCrossRef Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K et al (2009) Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24(10):1468–1474PubMedCrossRef
go back to reference Korczyn AD (2006) Management of sleep problems in Parkinson’s disease. J Neurol Sci 248(1–2):163–166PubMedCrossRef Korczyn AD (2006) Management of sleep problems in Parkinson’s disease. J Neurol Sci 248(1–2):163–166PubMedCrossRef
go back to reference Kumru H, Iranzo A, Carrasco E, Valldeoriola F, Marti MJ, Santamaria J, Tolosa E (2008) Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease. Sleep 31(10):1418–1421PubMed Kumru H, Iranzo A, Carrasco E, Valldeoriola F, Marti MJ, Santamaria J, Tolosa E (2008) Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease. Sleep 31(10):1418–1421PubMed
go back to reference Kunz D, Mahlberg R (2010) A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res 19(4):591–596PubMedCrossRef Kunz D, Mahlberg R (2010) A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res 19(4):591–596PubMedCrossRef
go back to reference Lee MA, Prentice WM, Hildreth AJ, Walker RW (2007) Measuring symptom load in idiopathic Parkinson’s disease. Parkinsonism Relat Disord 13(5):284–289PubMedCrossRef Lee MA, Prentice WM, Hildreth AJ, Walker RW (2007) Measuring symptom load in idiopathic Parkinson’s disease. Parkinsonism Relat Disord 13(5):284–289PubMedCrossRef
go back to reference Leeman AL, O’Neill CJ, Nicholson PW, Deshmukh AA, Denham MJ, Royston JP, Dobbs RJ, Dobbs SM (1987) Parkinson’s disease in the elderly: response to and optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol 24(5):637–643PubMedCrossRef Leeman AL, O’Neill CJ, Nicholson PW, Deshmukh AA, Denham MJ, Royston JP, Dobbs RJ, Dobbs SM (1987) Parkinson’s disease in the elderly: response to and optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol 24(5):637–643PubMedCrossRef
go back to reference Lees AJ, Blackburn NA, Campbell VL (1988) The nighttime problems of Parkinson’s disease. Clin Neuropharmacol 11(6):512–519PubMedCrossRef Lees AJ, Blackburn NA, Campbell VL (1988) The nighttime problems of Parkinson’s disease. Clin Neuropharmacol 11(6):512–519PubMedCrossRef
go back to reference Lemke MR, Brecht HM, Koester J, Reichmann H (2006) Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson’s disease. J Neurol Sci 248(1-2):266–270PubMedCrossRef Lemke MR, Brecht HM, Koester J, Reichmann H (2006) Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson’s disease. J Neurol Sci 248(1-2):266–270PubMedCrossRef
go back to reference Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, MacPhee G, Brown RG et al (2007) Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22(11):1623–1629PubMedCrossRef Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, MacPhee G, Brown RG et al (2007) Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22(11):1623–1629PubMedCrossRef
go back to reference Nisenzon AN, Robinson ME, Bowers D, Banou E, Malaty I, Okun MS (2011) Measurement of patient-centered outcomes in Parkinson’s disease: what do patients really want from their treatment? Parkinsonism Relat Disord 17(2):89–94PubMedCrossRef Nisenzon AN, Robinson ME, Bowers D, Banou E, Malaty I, Okun MS (2011) Measurement of patient-centered outcomes in Parkinson’s disease: what do patients really want from their treatment? Parkinsonism Relat Disord 17(2):89–94PubMedCrossRef
go back to reference Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL, EASE-PD Adjunct Study Investigators (2007) Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68(14):1108–1115PubMedCrossRef Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL, EASE-PD Adjunct Study Investigators (2007) Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68(14):1108–1115PubMedCrossRef
go back to reference Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B, SP 515 Investigators (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6(6):513–520PubMedCrossRef Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B, SP 515 Investigators (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6(6):513–520PubMedCrossRef
go back to reference Politis M, Wu K, Molloy S, Bain PG, Chaudhuri KR, Piccini P (2010) Parkinson’s disease symptoms: the patient’s perspective. Mov Disord 25(11):1646–1651PubMedCrossRef Politis M, Wu K, Molloy S, Bain PG, Chaudhuri KR, Piccini P (2010) Parkinson’s disease symptoms: the patient’s perspective. Mov Disord 25(11):1646–1651PubMedCrossRef
go back to reference Rektorova I, Rektor I, Bares M, Dostal V, Ehler E, Fanfrdlova Z, Fiedler J et al (2003) Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur J Neurol 10(4):399–406PubMedCrossRef Rektorova I, Rektor I, Bares M, Dostal V, Ehler E, Fanfrdlova Z, Fiedler J et al (2003) Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur J Neurol 10(4):399–406PubMedCrossRef
go back to reference Romigi A, Stanzione P, Marciani MG, Izzi F, Placidi F, Cervellino A, Giacomini P, Brusa L, Grossi K, Pierantozzi M (2006) Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson’s disease: an open label 24-hour polysomnographic study. J Neural Transm 113(12):1909–1913PubMedCrossRef Romigi A, Stanzione P, Marciani MG, Izzi F, Placidi F, Cervellino A, Giacomini P, Brusa L, Grossi K, Pierantozzi M (2006) Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson’s disease: an open label 24-hour polysomnographic study. J Neural Transm 113(12):1909–1913PubMedCrossRef
go back to reference Rye DB, Jankovic J (2002) Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology 58(3):341–346PubMedCrossRef Rye DB, Jankovic J (2002) Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology 58(3):341–346PubMedCrossRef
go back to reference Schrag A, Jahanshahi M, Quinn N (2000) What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry 69(3):308–312PubMedCrossRef Schrag A, Jahanshahi M, Quinn N (2000) What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry 69(3):308–312PubMedCrossRef
go back to reference Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, Reichmann H (2004) Detection of presymptomatic Parkinson’s Disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 19(10):1196–1202PubMedCrossRef Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, Reichmann H (2004) Detection of presymptomatic Parkinson’s Disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 19(10):1196–1202PubMedCrossRef
go back to reference Stocchi F, Barbato L, Nordera G, Berardelli A, Ruggieri S (1998) Sleep disorders in Parkinson’s disease. J Neurol 245(Suppl 1):S15–S18PubMedCrossRef Stocchi F, Barbato L, Nordera G, Berardelli A, Ruggieri S (1998) Sleep disorders in Parkinson’s disease. J Neurol 245(Suppl 1):S15–S18PubMedCrossRef
go back to reference Trenkwalder C (1998) Sleep dysfunction in Parkinson’s disease. Clin Neurosci 5(2):107–114PubMed Trenkwalder C (1998) Sleep dysfunction in Parkinson’s disease. Clin Neurosci 5(2):107–114PubMed
go back to reference Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P et al (2011a) Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26(1):90–99PubMedCrossRef Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P et al (2011a) Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26(1):90–99PubMedCrossRef
go back to reference Trenkwalder C, Kohnen R, Hogl B, Metta V, Sixel-Doring F, Frauscher B, Hulsmann J, Martinez-Martin P, Chaudhuri KR (2011b) Parkinson’s disease sleep scale–validation of the revised version PDSS-2. Mov Disord 26(4):644–652PubMedCrossRef Trenkwalder C, Kohnen R, Hogl B, Metta V, Sixel-Doring F, Frauscher B, Hulsmann J, Martinez-Martin P, Chaudhuri KR (2011b) Parkinson’s disease sleep scale–validation of the revised version PDSS-2. Mov Disord 26(4):644–652PubMedCrossRef
go back to reference Van den Kerchove M, Jacquy J, Gonce M, De Deyn PP (1993) Sustained-release levodopa in parkinsonian patients with nocturnal disabilities. Acta Neurol Belg 93(1):32–39PubMed Van den Kerchove M, Jacquy J, Gonce M, De Deyn PP (1993) Sustained-release levodopa in parkinsonian patients with nocturnal disabilities. Acta Neurol Belg 93(1):32–39PubMed
go back to reference Wolters ECh, Braak H (2006) Parkinson’s disease: premotor clinico-pathological correlations. J Neural Transm Suppl 70:309–319PubMedCrossRef Wolters ECh, Braak H (2006) Parkinson’s disease: premotor clinico-pathological correlations. J Neural Transm Suppl 70:309–319PubMedCrossRef
go back to reference Ziemssen T, Reichmann H (2007) Non-motor dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 13(6):323–332PubMedCrossRef Ziemssen T, Reichmann H (2007) Non-motor dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 13(6):323–332PubMedCrossRef
Metadata
Title
Sleep and non-motor symptoms in Parkinson’s disease
Authors
Antonia Maass
Heinz Reichmann
Publication date
01-04-2013
Publisher
Springer Vienna
Published in
Journal of Neural Transmission / Issue 4/2013
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-013-0966-4

Other articles of this Issue 4/2013

Journal of Neural Transmission 4/2013 Go to the issue

Neurology and Preclinical Neurological Studies - Review Article

The pharmacology of Tourette syndrome

Neurology and Preclinical Neurological Studies - Original Article

In vivo neurochemical imaging of olfactory dysfunction in Parkinson’s disease

Neurology and Preclinical Neurological Studies - Original Article

Non-motor symptoms of Parkinson’s disease: the patient’s perspective